LENZ Therapeutics (LENZ) Retained Earnings (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Retained Earnings data on file, last reported at -$268.6 million in Q1 2026.

• On a quarterly basis, Retained Earnings fell 68.31% year-over-year to -$268.6 million in Q1 2026; TTM through Mar 2026 was -$268.6 million, a 68.31% decrease from a year earlier, with the FY2025 full-year figure at -$227.1 million, down 56.63% from the prior year.
• Retained Earnings for Q1 2026 stood at -$268.6 million, down from -$227.1 million in the prior quarter.
• Over the last five years, Retained Earnings for LENZ reached as high as $548.2 million in Q3 2023 and fell as low as -$321.7 million in Q2 2023.
• Historically, Retained Earnings has averaged -$37.3 million across 5 years, with a median of -$122.1 million in 2024.
• On a YoY basis, Retained Earnings climbed as much as 34451.44% in 2023 and fell as far as 86093.2% in 2023.
• Year by year, Retained Earnings stood at $539.7 million in 2022, then tumbled by 117.65% to -$95.2 million in 2023, then plunged by 52.25% to -$145.0 million in 2024, then plunged by 56.63% to -$227.1 million in 2025, then decreased by 18.27% to -$268.6 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$268.6 million in Q1 2026, -$227.1 million in Q4 2025, and -$191.2 million in Q3 2025.